A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma

Table 7

The performance for the combination of serum lncRNAs and AFP in HC, HCC patients, CHB patients, and LC patients.

Method	AUC (95% CI)	SEN (%)	SPE (%)
HULC+AFP	0.848 (0.806-0.890)	81.4	73.4
MALAT1+AFP	0.820 (0.771-0.870)	62.0	92.3
Linc00152+AFP	0.906 (0.870-0.942)	85.3	84.0
PTTG3P+AFP	0.837 (0.793-0.881)	69.0	81.1
SPRY4-IT1+AFP	0.847 (0.803-0.890)	72.9	79.3
UBE2CP3+AFP	0.837 (0.792-0.882)	63.6	87.0
UCA1+AFP	0.878 (0.841-0.916)	71.3	88.8
Panel^#	0.912 (0.878-0.945)	82.9	88.2

HCC: hepatocellular carcinoma; HC: healthy control; CHB: chronic hepatitis B; LC: liver cirrhosis; AFP: alpha fetoprotein; AUC: area under curve; CI: confidence interval; SEN: sensitivity; SPE: specificity. ^#Panel includes Linc00152, UCA1, and AFP. Backward stepwise selection was used to determine the diagnostic values of serum lncRNAs for HCC. In this study, the combination of Linc00152, PTENP1, UCA1, and AFP (3-lncRNA panel) was chosen as the strongest panel for diagnostic markers. The other lncRNAs were excluded by a stepwise procedure. The regression equation: .